Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Study finds more PSA screening awareness needed among high-risk groups

Study finds more PSA screening awareness needed among high-risk groups

August 11, 2008

DURHAM, N.C. -- In one of the first examinations of PSA screening in younger men, a study published by researchers at Duke Medicine's Prostate Center finds that one-fifth of men under age 50 reported undergoing a prostate specific antigen (PSA) test to detect prostate cancer in the previous year, yet only one in three young black men reported ever having a PSA test in the previous year.

Overall, that's pretty good news for white men at average risk, researchers say, but not for black men or men with a family history who are at higher risk for developing the disease.




The findings appear online in the journal Cancer and will appear in the print version on Sept. 15.

"Our findings for black men are discouraging," says Judd W. Moul, MD, chief of the division of surgical urology at Duke and the paper's senior author. "We've been encouraging black men to get screened at age 40 or 45 for more than a decade, yet only one-third of these high-risk men reported being tested."

To assess how many men age 40-49 are being screened, Dr. Moul and Charles Scales, MD, a urology resident and researcher at Duke and the paper's first author, reviewed the 2002 Behavioral Risk Factor Surveillance System, an ongoing, state-based, random telephone survey of the U.S. population.

Their study showed several socio-demographic characteristics associated with PSA screening in young men. Young black men were more likely than young, white, non-Hispanic men to report having a PSA screening in the previous year. The survey also showed that younger Hispanic men were more likely to undergo PSA testing than younger white non-Hispanic men.

Health insurance, an ongoing physician-patient relationship, increasing obesity, and high household income and education level were also associated with having a recent PSA test.

"Our findings provide an important baseline assessment of PSA test use among young men as physicians debate whether to expand use of the PSA test in young men with risk-stratification strategies," says Scales.

Current guidelines encourage prostate cancer screening in men age 50 or older if they have a life expectancy of at least 10 years. High-risk groups, such as African Americans or those men with a positive family history, are encouraged to have a baseline screening at age 40.

There's plenty of debate related to these tests. Some question whether the recommended screening age of 50 should be made earlier for average-risk groups. Others debate whether too many PSA tests are being performed, and whether their financial incentives in physician practices may contribute to overuse. There's also an ongoing discussion about the possibility of more biopsies resulting from additional testing, and whether treatment-related side effects outweigh the years of life and money saved with less advanced disease management.

Moul believes the current guidelines should be changed to encourage baseline PSA Risk-Assessment starting at age 40.

"Even a subtle increase in the PSA value at that age is a pretty powerful predictor of future prostate disease and cancer," says Moul. "Right now, only one in five men are getting a PSA test, which is encouraging, but I wish the number was higher. This research suggests we can do a better job of screening men at age 40, and a better job in high-risk men. There's a huge population of African American men who are not getting screened, and men with a family history of prostate cancer who are under 50 are also not getting screened."

Duke University Medical Center



Related Prostate Specific Antigen Current Events and Prostate Specific Antigen News Articles Prostate Specific Antigen Current Events and Prostate Specific Antigen News RSS Prostate Specific Antigen Current Events and Prostate Specific Antigen News RSS
A card-swipe for medical tests
University of Utah scientists successfully created a sensitive prototype device that could test for dozens or even hundreds of diseases simultaneously by acting like a credit card-swipe machine to scan a card loaded with microscopic blood, saliva or urine samples.

New Catheter-less Technique May Ease the Pain and Discomfort of Prostate Cancer Recovery
To ease the pain of recovery following prostate cancer surgery, physician-scientists have developed an innovative and patient-friendly approach that eliminates the use of a penile urinary catheter.

Anti-inflammatory drugs may mask prostate cancer marker
Regular use of nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, may reduce serum levels of the prostate biomarker, PSA (prostate specific antigen), and hence may alter the detection of prostate cancer in individuals who take these medications.

Health risk behaviors associated with lower prostate specific antigen awareness
According to a study conducted at Columbia University Mailman School of Public Health, health risk behaviors such as smoking and obesity are associated with lower awareness of the Prostate Specific Antigen (PSA), which could lead to a lower likelihood of undergoing actual prostate cancer screening.

Why a common treatment for prostate cancer ultimately fails
Some of the drugs given to many men during their fight against prostate cancer can actually spur some cancer cells to grow, researchers have found. The findings were published online this week in a pair of papers in the Proceedings of the National Academy of Sciences.

Prostate cancer patients undergoing hormone therapy may experience cognitive effects
A recent review of the literature has found that hormone deprivation therapy, a commonly used treatment for prostate cancer, may have subtle adverse effects on cognition in patients-- such as in the ability to recall and concentrate.

Radiation therapy prolongs life in men with recurrent prostate cancer
Men whose tumors recur after prostate cancer surgery are three times more likely to survive their disease long term if they undergo radiotherapy within two years of the recurrence.

OHSU Cancer Institute finds that drug stimulated immune system in prostate cancer
In a multi-site study, Oregon Health & Science University Cancer Institute researchers have found that a drug called Ipilimumab, also known as MDX-010, works to stimulate the body's own immune system to fight prostate cancer. The drug was found to be effective in study participants with a serious type of prostate cancer - one where the tumor has spread and was resistant to hormonal treatment and, in some cases, also to chemotherapy.

MR imaging accurately determines prostate cancer treatment failure
Dynamic contrast-enhanced MRI (DCE-MRI) plus diffusion weighted imaging (DWI) can accurately diagnose residual or recurrent prostate cancer in patients treated with high-intensity focused ultrasonic ablation, a new study shows.

New data show benefit of finasteride in preventing prostate cancer
A comprehensive re-evaluation of the largest prostate cancer prevention study ever completed produced new findings suggesting that men and their doctors should consider a more aggressive approach that includes finasteride to prevent the development of prostate cancer.
More Prostate Specific Antigen Current Events and Prostate Specific Antigen News Articles


Prostate Specific Antigen
by Brawer

This state-of-the-art reference provides a comprehensive review of prostate specific antigen (PSA) and related prostate markers-examining velocity, density, and age-specific reference ranges for increased sensitivity in PSA tumor identification and selection of patient therapies. Supplemented with helpful drawings, photographs, and tables that reinforce and clarify essential issues! Considering...

Prostatitis confounds PSA velocity for prostate cancer risk assessment.(News)(prostate-specific antigen levels) : An article from: Family Practice News
by Diana Mahoney

This digital document is an article from Family Practice News, published by Thomson Gale on April 15, 2006. The length of the article is 512 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:...

Order fewer biopsies with complexed PSA screening. (Prostate Cancer Predictor).(prostate-specific antigen ): An article from: Family Practice News
by Damian McNamara

This digital document is an article from Family Practice News, published by International Medical News Group on March 1, 2003. The length of the article is 616 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Booklet provides patients with pros, cons of PSA screening. (Award-Winning Guide).(prostate-specific antigen)("The PSA Test for Prostate Cancer: Is It ... An article from: Family Practice News
by Michele G. Sullivan

This digital document is an article from Family Practice News, published by International Medical News Group on February 1, 2003. The length of the article is 519 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Interpreting the PSA - the key to adequate prostate cancer screening. (prostate-specific antigen): An article from: Medical Update
by Edwin W. Brown

This digital document is an article from Medical Update, published by Benjamin Franklin Literary & Medical Society, Inc. on December 1, 1996. The length of the article is 1093 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

Most men support informed consent for PSA testing. (Nhanes Survey Results).(prostate-specific antigen): An article from: Family Practice News
by Doug Brunk

This digital document is an article from Family Practice News, published by International Medical News Group on May 1, 2003. The length of the article is 2553 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

New PSA measures may refine cancer screening; assays for free and complexed PSA. (prostate-specific antigen).(Clinical Rounds): An article from: Internal Medicine News
by Mitchel L. Zoler

This digital document is an article from Internal Medicine News, published by International Medical News Group on October 1, 2003. The length of the article is 427 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

New PSA measures refine cancer screening: free and complexed PSA.(Clinical Rounds)(prostate-specific antigen): An article from: Family Practice News
by Mitchel L. Zoler

This digital document is an article from Family Practice News, published by International Medical News Group on January 1, 2004. The length of the article is 445 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

Pro & Con: Should men be encouraged to have PSA testing for prostate cancer.(prostate-specific antigen): An article from: Internal Medicine News

This digital document is an article from Internal Medicine News, published by International Medical News Group on January 15, 2002. The length of the article is 1024 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web...

Complexed PSA May Improve Ca Diagnosis.(prostate-specific antigen, cancer): An article from: Family Practice News
by David R. Branch

This digital document is an article from Family Practice News, published by International Medical News Group on May 1, 1999. The length of the article is 3741 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation...

© 2008 BrightSurf.com